Foghorn Therapeutics (FHTX) Investor presentation summary

Strategic partnerships and financial position

• Entered a major collaboration with Lilly, including $380 million upfront and a 50/50 U.S. economic split on two lead programs, with additional royalties and up to $1.3 billion in milestones possible across three programs.

• Maintains $158.9 million in cash and equivalents as of December 2025, plus $50 million from a January 2026 financing, providing a cash runway into H1 2028.

Pipeline and platform highlights

• Focuses on chromatin biology, targeting up to 50% of tumors and addressing over 500,000 patients with current pipeline.

• Lead asset FHD-909, a selective SMARCA2 inhibitor, is in Phase 1 for SMARCA4-mutant cancers, partnered with Lilly.

• Additional preclinical programs include selective degraders for SMARCA2, CBP, EP300, and ARID1B, with IND-enabling studies planned for 2026.

Clinical and preclinical data

• FHD-909 exploits the synthetic lethal relationship between SMARCA2 and SMARCA4, showing strong in vivo activity and synergy with standard therapies and KRAS inhibitors in NSCLC models.

• Selective CBP and EP300 degraders demonstrate potent, selective degradation, anti-tumor efficacy, and improved tolerability in preclinical models, including resistant multiple myeloma and breast cancer.

• ARID1B degraders show robust degradation and downstream gene effects, progressing toward in vivo proof-of-concept.